This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohen, C. J. Articles by Pile, O. H. Search for Related Content PubMed Articles by Cohen, C. J. Articles by Pile, O. H. Social Bookmarking                         What's this?

Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens

Community Research Initiative of New England in Brookline, Massachusetts

Peter J. Piliero, MD

Department of Medicine, at Albany Medical College in Albany, New York

Orlando H. Pile, MD

Communicable Diseases for the Los Angeles County Sheriff's Department, Twin Tower Correctional Facility, in Los Angeles, California

The correctional system presents unique challenges that can interfere with the HIV-infected inmate's ability to adhere to antiretroviral treatment. One mechanism to facilitate adherence is twice-daily dosing. This article compares safety and efficacy data on five currently available protease inhibitors - amprenavir, indinavir, nelfmavir, saquinavir soft gel capsules, and ritonavir - and examines their adaptability to twice-daily dosing. Movements toward once-daily dosing are discussed, as is the development of new dual protease inhibitor regimens. Simplified dosing strategies along with a comprehensive continuum of care have important benefits for adherence as well as for the inmate's long-term well-being.

Journal of Correctional Health Care, Vol. 7, No. 1, 61-90 (2000)
DOI: 10.1177/107834580000700103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?